Stay updated on EDP-305 Safety and Efficacy in NASH Clinical Trial
Sign up to get notified when there's something new on the EDP-305 Safety and Efficacy in NASH Clinical Trial page.

Latest updates to the EDP-305 Safety and Efficacy in NASH Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant content removal regarding the Phase 2b study of EDP-305 for Non-Alcoholic Steatohepatitis (NASH), including details about the study's design, inclusion and exclusion criteria, and the investigational drug's efficacy and safety. The revision number has also been updated from v2.14.4 to v2.15.0.SummaryDifference30%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
- Check87 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference0.8%
Stay in the know with updates to EDP-305 Safety and Efficacy in NASH Clinical Trial
Enter your email address, and we'll notify you when there's something new on the EDP-305 Safety and Efficacy in NASH Clinical Trial page.